Article Text

Download PDFPDF

Tumour necrosis factor α inhibitor treatment for sarcoidosis refractory to conventional treatments: a report of five patients
  1. C Pritchard,
  2. K Nadarajah
  1. Rheumatology Specialty Center, 2400 Maryland Road, Suite 40, Willow Grove, PA 19090, USA
  1. Correspondence to:
    Dr K Nadarajah;
    knadarajahamh.org

Abstract

Objective: To study the effectiveness of tumour necrosis factor α (TNFα) inhibitor treatment for sarcoidosis refractory to conventional treatments.

Methods: Five patients (two men, three women) were treated with infliximab. All patients received a loading dose of 3 mg/kg at 0, 2, and 6 weeks and then maintenance infusions every 4–8 weeks. Patients had their dose increased or the dosing interval reduced when the disease relapsed. These patients had active disease despite treatment with corticosteroids and other immunomodulatory agents. All patients had a negative tuberculin skin test.

Results: Sarcoidosis in all patients improved significantly without any serious adverse reactions.

Conclusion: This study suggests that TNFα is effective in patients for whom conventional treatment fails.

  • tumour necrosis factor α
  • sarcoidosis
  • infliximab
  • ACE, angiotensin converting enzyme
  • CT, computed tomography
  • IL, interleukin
  • MRI, magnetic resonance imaging
  • TNFα, tumour necrosis factor α
View Full Text

Statistics from Altmetric.com

Footnotes

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.